NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Public ClinicalTrials.gov record NCT03589339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Study identification
- NCT ID
- NCT03589339
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Nanobiotix
- Industry
- Enrollment
- 145 participants
Conditions and interventions
Conditions
- Immunotherapy
- Metastasis From Malignant Melanoma of Skin (Disorder)
- Metastasis From Malignant Tumor of Bladder (Disorder)
- Metastasis From Malignant Tumor of Cervix
- Metastasis From Malignant Tumor of Liver
- Metastatic NSCLC
- Metastatic Renal Cell Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Microsatellite Instability-High Solid Malignant Tumour
- Radiotherapy
- Squamous Cell Carcinoma of Head and Neck
Interventions
- NBTXR3 Drug
- Nivolumab Drug
- Pembrolizumab Drug
- SABR Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2019
- Primary completion
- Apr 29, 2027
- Completion
- Aug 29, 2027
- Last update posted
- Oct 23, 2025
2019 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94158 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30308 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | — |
| Christus St. Vincent Regional Cancer Center | Santa Fe | New Mexico | 87505 | — |
| Northwell Health | Manhasset | New York | 11030 | — |
| University of North Carolina, School of Medicine | Chapel Hill | North Carolina | 27516 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| St Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03589339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03589339 live on ClinicalTrials.gov.